Genentech Hanmi Pharmaceutical $2.3B Deal Structure Breakdown

$190 million upfront for a Phase 1 peptide. On August 24, 2026, Genentech signed a license agreement with Hanmi Pharmaceutical for HM17321, a metabolic peptide asset, in a deal with a headline value of $2.3 billion. Total milestones account for $2.1 billion. Royalty terms remain undisclosed. This is one of the largest Phase 1 metabolic licensing deals in the past 24 months, and the Hanmi Pharmaceutical Genentech deal terms tell a clear story: Roche's U.S. subsidiary is paying a premium to stay relevant in a therapeutic area where it has been conspicuously absent while the rest of large pharma fights over GLP-1 receptor agonist successors.

Deal Structure Breakdown

Let's start with the math that matters.

The upfront-to-TDV ratio of 8.3% sits slightly above the median for Phase 1 metabolic licensing deals tracked through metabolic Deal Benchmarks, where the range typically spans 5–12%. That ratio reveals a deliberate posture: Genentech is willing to pay meaningful money now — $190M is not a token option payment — but is pushing substantial risk into back-loaded milestones that only trigger on clinical and commercial proof.

With $2.1B in milestones, the implied milestone-to-upfront multiple is 11.1x. For context, typical Phase 1 licensing transactions in metabolic sit closer to 7–9x. The elevated multiple suggests two things. First, Genentech negotiated aggressively on the upfront — Hanmi likely pushed for $250M or more given the competitive dynamics (more on that below). Second, Hanmi accepted the structure because the milestone waterfall is probably front-loaded toward Phase 2 data readouts and first regulatory approval, where the probability of success for peptide therapeutics in metabolic indications has been climbing — driven largely by the precedent set by GLP-1 and dual-agonist programs.

Royalties remain undisclosed, but given the deal economics and Hanmi's track record as a licensor, expect tiered royalties in the low-to-mid teens range, potentially escalating to high teens on blockbuster sales thresholds. Hanmi has historically secured strong royalty positions — their LAPS biology platform gives them leverage because the underlying technology is proprietary and non-substitutable.

An 8.3% upfront-to-TDV ratio on a Phase 1 asset is neither a bargain nor an overpay — it is the price of entry into a market where Genentech has no clinical-stage metabolic peptide of its own.

Competitive Context — Why Genentech and Why HM17321

Genentech's parent company Roche has been the most notable absentee in the metabolic peptide race. While Novo Nordisk, Lilly, Amgen, Pfizer, AstraZeneca, and Viking Therapeutics have all staked claims across GLP-1, GIP, amylin, and glucagon receptor biology, Roche has largely watched from the sidelines. The Hanmi Pharmaceutical Genentech deal structure signals that the watching is over.

HM17321 fits squarely into Hanmi's LAPS (Long-Acting Protein/Peptide Discovery) technology platform — the same platform that generated efinopegdutide (licensed to MSD) and other next-generation metabolic peptides. LAPS-enabled molecules are differentiated by extended half-lives and the ability to engineer multi-agonist activity, giving them a pharmacokinetic edge that pure sequence-based peptides struggle to match.

Hanmi has been the most prolific licensor of metabolic peptide assets in Asia over the past five years. Their willingness to out-license rather than develop independently has created a robust deal flow, but it also means every major pharma company has had the opportunity to evaluate their pipeline. Genentech's decision to move on HM17321 now — at Phase 1 — indicates either differentiated early clinical signals or a fear that the asset would go to a competitor if they waited.

Three competitive dynamics drove this timing:

• Pipeline scarcity at the top: The number of novel metabolic peptide mechanisms that are not already partnered or in advanced development is shrinking rapidly. By mid-2026, most dual- and tri-agonist programs with credible data packages are spoken for. Waiting for Phase 2 data would have meant competing against a broader set of bidders with more conviction — and paying a significantly higher upfront.
• Roche's oncology-to-metabolic rebalancing: Roche has signaled through multiple executive statements and R&D budget reallocations that metabolic disease is a growth priority. HM17321 gives Genentech a clinical-stage asset that could, on an accelerated timeline, deliver Phase 2 data by late 2027 or early 2028 — fast enough to remain competitive with second-wave metabolic entries.
• Hanmi's negotiating leverage: Hanmi reportedly engaged multiple potential licensees in a structured process. The $190M upfront, while below what some bidders may have offered, was paired with a milestone structure and likely royalty terms that maximized Hanmi's long-term economics. Genentech's brand and commercial infrastructure in the U.S. and EU made them a preferred partner for Hanmi, even if the upfront was not the highest bid.

What This Means for Similar Assets

If you are a biotech founder or BD lead sitting on a Phase 1 peptide asset targeting metabolic indications, the Hanmi Pharmaceutical Genentech deal terms just reset your valuation conversation. Here is what you should internalize:

Upfront Benchmarks

$190M for a Phase 1 peptide in metabolic is in the top quartile. But Hanmi is not a typical biotech — they bring a validated technology platform (LAPS) with multiple prior out-licensing successes. If your asset is a single-program company without a platform story, calibrate your upfront expectations to the $50M–$120M range for Phase 1 metabolic peptide deals. Use the Solidus calculator to run your own benchmarks against comparable transactions.

Milestone Structures

The 11.1x milestone-to-upfront multiple here is a ceiling, not a baseline. Expect 7–9x for most Phase 1 metabolic transactions. Buyers are willing to load milestones heavily if the upfront is contained, which means you should negotiate for milestone triggers that align with near-term de-risking events — Phase 2 readouts, IND acceptances in major markets, first regulatory submission — rather than distant commercial sales thresholds that may never materialize.

Royalty Expectations

Undisclosed in this deal, but the metabolic space is converging on low-to-mid teens royalties for Phase 1 out-licensing, with escalation clauses tied to tiered annual net sales. If you are negotiating below 10% base royalties for a differentiated metabolic peptide, you are leaving economics on the table. The data across metabolic Deal Benchmarks supports this range consistently.

The Modality Premium

Peptides in metabolic carry a modality premium that small molecules and antibodies in the same therapeutic area do not command. The reason is straightforward: the clinical and commercial validation of GLP-1 receptor agonists has created a regulatory and payer pathway that de-risks development timelines. Buyers are pricing that de-risking into their bids. If your metabolic asset is a peptide, you are negotiating from a position of strength. If it is a small molecule with a metabolic peptide-like mechanism, expect a 20–30% discount on upfront and TDV relative to the peptide benchmarks.

Benchmark your own metabolic deal against 1,500+ comparable transactions using the Ambrosia calculator. The Hanmi-Genentech deal is already indexed and available for side-by-side comparison with your asset's profile.

Frequently Asked Questions

What is HM17321 and why is it valuable to Genentech?

HM17321 is a metabolic peptide developed by Hanmi Pharmaceutical using their proprietary LAPS technology platform, which enables long-acting and multi-agonist peptide design. The asset is currently in Phase 1 clinical development. It is valuable to Genentech because Roche has had no meaningful clinical-stage metabolic peptide program, and HM17321 offers a differentiated mechanism with potential for best-in-class pharmacokinetics. The LAPS platform has already produced multiple successfully out-licensed molecules, giving Genentech confidence in the underlying technology's translatability.

How does the Hanmi Pharmaceutical Genentech deal structure compare to other Phase 1 metabolic licensing deals?

The $190M upfront places this deal in the top quartile for Phase 1 metabolic licenses. The 8.3% upfront-to-TDV ratio and 11.1x milestone-to-upfront multiple both exceed median benchmarks of ~7% and ~8x respectively, as tracked across metabolic Deal Benchmarks. The elevated multiples reflect both the competitive intensity in the metabolic space and Hanmi's platform-level negotiating leverage. Deals for similar-stage metabolic peptides without a validated platform behind them have typically landed in the $50M–$120M upfront range with TDVs of $800M–$1.5B.

Why were royalties undisclosed and what range is likely?

Undisclosed royalties are standard in approximately 40% of metabolic licensing transactions, often because the royalty structure includes complex tiering, sales-based escalation, and potential step-downs post-patent expiry that both parties prefer to keep confidential. Based on comparable Phase 1 metabolic peptide deals and Hanmi's historical licensing terms, the likely royalty range is low-to-mid teens (12–16%), with potential escalation to high teens on annual net sales exceeding $2–3 billion. Hanmi's prior deals have consistently secured royalties at or above the median for the therapeutic area.